A New HIV Shot Arrives in Africa — Is It A Gift or Something Else?
“This is more than medicine, it’s a pathway to a safer, stronger, and healthier future.” — (U.S. Embassy, Zimbabwe), but it’s not just about the science; it’s about the approach and the intent.
Lenacapavir, marketed as Sunlenca, is an antiretroviral drug for HIV recommended for individuals with multidrug resistance who have limited treatment options.
At the end of September 2025, the US Embassy in Zimbabwe posted on X, congratulating Zimbabwe for being selected as one of the African countries to first receive the drug. While reading the comments, I noticed that many people were skeptical, questioning the timing and potential hidden agendas.
This inspired me to write a piece encouraging everyone to consider both perspectives. I included the scientific aspects of the drug and emphasized that, while it appears revolutionary on paper, science alone is not enough, there are political issues that still need to be addressed.
The Scientific Promise: What Makes Lenacapavir So Remarkable
As a science educator and bioinformatics researcher, I have spent years studying how viruses evolve, how drugs interact with biological systems, and how public health decisions ripple through communities.
When I read the announcement that Zimbabwe and nine other sub-Saharan African countries had been selected to pilot lenacapavir, I paused.
Lenacapavir is a unique antiretroviral treatment, as it is the first of its kind to function as an HIV capsid inhibitor. This means it specifically targets the HIV protein shell, known as the capsid, which is essential for the virus’s replication, assembly, and ability to infect new cells.
Most HIV drugs act after the virus has already entered host cells and begun replication. Lenacapavir intervenes earlier, disrupting multiple stages of the viral lifecycle as shown in the diagram below:
Understanding the HIV Capsid: The Viral Shell That Holds the Key
The HIV capsid is a cone-shaped structure made up of repeating units of the capsid protein (CA). It serves to protect the viral RNA and enzymes as they travel into the host cell and plays a crucial role in the uncoating process once the virus is inside. This shell is not only structural but also functional, dynamic, and essential for the survival of HIV.
Lenacapavir binds to specific sites on the capsid and interferes with its ability to disassemble properly. It also disrupts the formation of new capsids during viral assembly, leading to malformed, hyper-stable virus particles that cannot infect target cells.
A recent study shows that lenacapavir exerts opposing effects on the formation of CA pentamers and hexamers, key intermediates in capsid assembly. By stabilizing hexameric lattices and impairing pentamer formation, it causes structural chaos within the virus.
Lenacapavir operates through a dual-action mechanism that blocks both the entry and exit of viruses, giving it a unique potency. It has shown picomolar-level efficacy in laboratory tests and has produced impressive results in clinical trials.
In Phase 3 studies (see the table below), lenacapavir achieved a prevention rate of 100% in cisgender women and a 96% prevention rate in cisgender men who have sex with men, as well as in transgender and gender non-binary participants.
The Long-Acting Advantage — One Injection, Six Months of Protection
What truly distinguishes lenacapavir is its long-acting formulation. Given as a subcutaneous injection just twice a year, it provides sustained protection without the daily hassle of taking pills. This is revolutionary for individuals who struggle with adherence due to factors such as stigma, mobility issues, or simply forgetting.
Think about the possibilities:
- Discreet protection for young women, sex workers, and LGBTQI individuals who face judgment or violence.
- Reduced healthcare visits, easing pressure on overstretched systems and freeing up resources.
- Improved adherence, especially in rural and underserved communities where access to clinics is limited.
This represents science at its finest — a single injection providing six months of reassurance.
Why Sub-Saharan Africa? The Rationale Behind the Rollout
To be fair, there are clear scientific and public health reasons why sub-Saharan African countries are being prioritised for lenacapavir’s rollout.
1. High HIV Burden
Sub-Saharan Africa accounts for nearly two-thirds of global HIV infections. Countries like South Africa, Nigeria, Kenya, and Zimbabwe have some of the highest prevalence rates in the world. Targeting prevention here could have the greatest impact on global incidence.
2. Established Infrastructure
Thanks to decades of work by PEPFAR, the Global Fund, and local ministries of health, many African countries have robust HIV testing, monitoring, and treatment systems in place. These systems are capable of supporting the logistics of a long-acting injectable.
3. Proven Community Engagement
African health workers, educators, and civil society groups have built trust and resilience in the face of stigma and misinformation. Community-led initiatives have shown that when people are empowered, they respond with commitment and care.
4. Diverse Populations for Research
From urban centers to rural clinics, the region offers varied demographics for studying real-world effectiveness. This diversity is scientifically valuable and ethically necessary.
Get Milton Simba Kambarami’s stories in your inbox
Join Medium for free to get updates from this writer.
In summary, Africa is not just vulnerable but also prepared, which is why it has been chosen. Studies show that the drug has been tested on various global ethnicities. However, being prepared doesn’t eliminate risks, and gratitude shouldn’t suppress essential questions.
The Politics: Why Sympathy Now, When So Much Else Is Being Denied?
I cannot ignore the contradictions.
Why should the United States extend its medical generosity to sub-Saharan Africa now, especially when African scholars are being denied visas, funding for African-led research is being cut, NGOs are shrinking, and the global narrative continues to depict us as hypersexual, intellectually inferior, and perpetually dependent?
I’ve witnessed these stereotypes myself…the jokes, the dismissals, the assumptions. That Africans are overly sexual, that we can’t follow instructions, that we’re in constant need of saving. And now, out of nowhere, a miracle drug is being offered to us?
Is this compassion or containment?
Is lenacapavir a gift — or a geopolitical gesture?
I want to believe in the science. I do. But I also know that science does not arrive in a vacuum. It is shaped by politics, power, and history.
The Sub-Saharan Dilemma: Between Gratitude and Grievance
Sub-Saharan Africa is home to brilliant scientists, resilient health systems, and youth-led movements that challenge the status quo. Yet we are rarely treated as equals.
If lenacapavir is to succeed, it must be more than a pilot project. It must be rooted in:
- Local Leadership
African researchers, clinicians, and educators must be at the forefront of implementation, monitoring, and education. We must not be passive recipients, we must be active architects.
2. Transparent Funding Models
We need clarity on who pays, for how long, and under what conditions. Will lenacapavir remain free?
Will governments be expected to shoulder costs once donor enthusiasm fades?
3. Respectful Engagement
The rollout must break down stereotypes and prioritize African dignity. It must acknowledge that our communities are not merely places of disease — they are also places of resilience, innovation, and hope.
“We must not confuse access with autonomy. A drug is not empowerment unless it comes with choice, context, and control.” — Anonymous
The Inconclusive: What Are We Really Being Offered?
This is where I become less of a scientist and more of a citizen.
Imagine you are a young woman living in rural Malawi. You have heard about this free injection that is said to be effective. However, you recall a time when ARVs were scarce. You have witnessed how stigma can silence the truth.
Do you take the shot?
As a policymaker in Nigeria, you are balancing donor expectations, national priorities, and community concerns. You understand that lenacapavir could save lives, but you also recognize that dependency on it can be dangerous.
Do you endorse the rollout?
These are not hypothetical questions. They are real, urgent, and unresolved.
The Mirror: What Should We Ask Ourselves?
As Africans, as scientists, as educators, we must ask:
- Are we being seen as partners, or as problems to be managed?
2. Can we trust a system that offers medicine but denies mobility, collaboration, and respect?
3. Will we build health futures rooted in sovereignty, or in dependency?
I want my students to grow up in a world where science empowers, not controls. Where prevention is a choice, not a prescription. Where Africa is not just a testing ground, but a source of innovation, leadership, and dignity.
Conclusion: Between the Lines of Progress
Lenacapavir is a marvel of molecular engineering. But its true test lies not in the lab, but in the lived realities of sub-Saharan Africans. This is a moment to celebrate science, yes — but also to interrogate power, equity, and the politics of health.
I wrote this not to dismiss the drug, but to deepen the conversation. Let this article be a prompt, not a conclusion. Let every reader ask:
What does prevention mean in a world that restricts movement, silences voices, and stereotypes bodies? What kind of future are we building, one injection at a time?
I’ve simplified the science of Lenacapavir in this article to make the message clear. If you enjoyed the scientific aspects, please leave a comment so I can research further and write a more in-depth exploration of Lenacapavir’s science.
Edit: I have written the in-depth research article for Lenacapavir for those who are interested in the nitty gritties of the drug.
